Long-acting formulations of atypical antipsychotics: Time to reconsider when to introduce depot antipsychotics

CNS Drugs

Volumn 21, Issue 6, 2007, Pages 441-448

  Chue, Pierre ^a,c   Emsley, Robin ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; RISPERIDONE; ZIPRASIDONE;

AGGRESSION; AGITATION; ANXIETY; BODY WEIGHT; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; GYNECOMASTIA; HUMAN; INJECTION SITE PAIN; INSOMNIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RHINITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS; SCHIZOPHRENIA; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 34249821946     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721060-00001     Document Type: Review

References (79)

1. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006; 36 (10): 1349-62
2. Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psych Res 2007; 41 (8): 659-66
3. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 163 (4): 743-5
4. Robinson DG, Woerner MG, Delman HM, et al. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31 (3): 705-22
5. Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003; 63 (21): 2265-83
6. Malla A, Norman R, Schmitz N, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med 2006; 36 (5): 649-58
7. McEvoy JP, Johnson J, Perkins D, et al. Insight in first-episode psychosis. Psychol Med 2006; 36 (10): 1385-93
8. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002; 57 (2-3): 209-19
9. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psych 2003; 64: 24-33
10. Schooler N. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003; 64: 14-7
11. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47 (5): 741-73
12. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006; 67 (5): 15-8
13. Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry 2005; 50: 7-57S
14. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39 (1-2): 1-30
15. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd ed. Arlington (VA): American Psychiatric Association, 2004
16. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65 (4): 500-8
17. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64: 5-19
18. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8 (1): 55-66
19. Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63 (5): 493-512
20. Moller HJ. Antipsychotic agents: gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiatry 2005; 20 (5-6): 379-85
21. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003; 64: 34-40
22. Dursun SJ. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia. J Psychopharmacol 2005; 19 (5): 3-4
23. Keith SJ, et al. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 2004; 65 (1): 120-31
24. Jarboe KS, Littrell K, Tugrul K. Long-acting injectable risperidone: an emerging tool in schizophrenia treatment. J Psychosoc Nurs Ment Health Serv 2005; 43 (12): 25-33
25. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004; 14 (2): 87-92
26. Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002; 59: S10-5
27. Chen EY, Harrison G, Standen PJ. Management of first episode psychotic illness in Afro-Caribbean patients. Br J Psychiatry 1991; 158: 517-22
28. Valenstein M, Copeland LA, Owen R, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001; 62 (7): 545-51
29. Tiihonen J, Walhbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333 (7561): 224-7
30. Kane JM, Rifkin A, Quitkin F, et al. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982; 39: 70-3
31. Harrison TS, Goa LA. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004; 18 (2): 113-32
32. Chue P. Risperidone long-acting injection. Expert Rev Neurotherapeutics 2003; 3 (4): 89-100
33. Thompson S, Rey JA. Risperdal consta: the first long-acting atypical antipsychotic agent. P&T 2004; 29 (9): 555-62
34. Faludi G. The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia [in Hungarian]. Neuropsychopharmacol Hung 2005; 7 (1): 22-7
35. Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004; 26 (12): 1994-2002
36. Lemon M. Risperidone long-acting injection: a brief overview. S D J Med 2004; 57 (5): 171-2
37. Love RC, Conley RJ. Long-acting risperidone injection. Am J Health Syst Pharm 2004; 61 (17): 1792-800
38. Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann Pharmacother 2004; 38 (12): 2122-7
39. Curran MP. Long-acting injectable risperidone. Int J Clinical Psychopharmacology 2006; 14 (2): 107-25
40. Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin 2006; 22 (2): 241-55
41. Martin SD, Libretto SE, Pratt DJ, et al. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003; 19 (4): 298-305
42. Marder SR, Conley R, Ereshefsky L, et al. Clinical guidelines: dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003; 64: 41-6
43. Taylor DM, Young CL, Mace S, et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004; 65 (8): 1076-83
44. Marsand P, Gupta S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging 2003; 20 (15): 1099-110
45. Chue P. Long-acting risperidone injection: efficacy, safety and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat 2007. E-pub
46. Keith S, Nick B, Emsley R, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004; 55 (9): 997-1005
47. Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005; 19: 5-14
48. Saleem P, Firmino H, Parellada E, et al. Young patients (18-30 years) with schizophrenia and schizoaffective disorder: results of direct switching to long-acting injectable risperidone (StoRMi trial) [abstract]. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13: Davos
49. Lasser R, Bossie CA, Zhu Y, et al. Long-acting risperidone in young adults with schizophrenia or schizoaffective disorder [abstract]. 157th American Psychiatric Association Annual Meeting; 2004 May 1-6: New York
50. Emsley R, Oosthuizen P, Koem L, et al. A trial of risperidone long-acting injectable in first episode psychosis [abstract]. American Psychiatric Association Annual Meeting; 2005 May 21-26: Atlanta (GA)
51. Emsley R, Oosthuizen P, Koem L, et al. Safety and efficacy of long-acting risperidone as a first-line treatment for first-episode psychosis: 6-month interim analysis [abstract]. XIIIth Biennial Winter Workshop of Schizophrenia Research; 2006 Feb 4-10: Davos
52. Möller H, Llorca PM, Sachetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20: 121-30
53. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry 2003; 64: 1250-7
54. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC. American Psychiatric Association, 1994
55. Malla A, Binder C, Chue P. Comparison of long-acting injectable risperidone and oral novel antipsychotic drugs for treatment in early phase of schizophrenia spectrum psychosis [abstract]. 61st Annual Convention Society of Biological Psychiatry; 2006 May 18-20: Toronto (ON)
56. Rummel C, Hamann J, Kissling W, et al. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev 2003; (4): CD004410
57. Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003; 63 (21): 2265-83
58. Lambert M, Conus P, Lambert T, et al. Pharmacotherapy of first-episode psychosis. Expert Opin Pharmacother 2003; 4 (5): 717-50
59. Ohlsen RI, O'Toole MS, Purvis RG, et al. Clinical effectiveness in first-episode patients. Eur Neuropsychopharmacol 2004; 14 (4): S445-51
60. Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety consider ations. Drugs 2005; 65 (8): 1113-38
61. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. HGDH Study Group. Am J Psychiatry 2003; 160 (8): 1396-404
62. Chue PS, D'Hoore P, Ramstack JM. Sustained drug delivery optimizes long-term treatment of patients with schizophrenia. Acta Neuropsychiatrica 2004; 16 (6): 319-26
63. Chue P. Compliance and convenience: do physicians and patients see depot medication differently? Acta Neuropsychiatrica 2004; 16: 314-38
64. Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004; 13: 811-6
65. Patel MX, De Zoysa N, Baker D, et al. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs 2005; 12 (2): 237-44
66. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83-9
67. Chue P, Llorca P, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005; 5: 266-74
68. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300-7
69. Svedberg B, Backenroth-Ohsako G, Lutzen K. On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs 2003; 12 (2): 110-8
70. Fleischhacker WW, Lasser R, Mehnert A. Perceived functioning and well-being and association with psychiatric symptomatology in clinically stable schizophrenia patients treated with long-acting risperidone for 1 year. Br J Psychiatry 2005; 187: 131-6
71. Nasrallah HA, Duchesne I, Mehnert A, et al. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004; 65: 531-6
72. Lindenmayer JP, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005; 20 (4): 213-21
73. Mannaert E, Vermeulen A, Remmerie B, et al. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale 2005; 31 (5): 609-15
74. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003; 64 (16): 18-23
75. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005; 6 (3): 129-37
76. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomised trial. Early Psychosis Global Working Group. Am J Psychiatry 2005; 162 (5): 947-53
77. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999; 25: 721-9
78. Lambert T. Selecting patients for novel long-acting antipsychotic therapy. Australas Psychiatry 2006; 14 (1): 38-42
79. Fraser R, Berger G, Killackey E, et al. Emerging psychosis in young people: part 3. Key issues for prolonged recovery. Australian Family Physician 2006; 35 (5): 329-33